400=007=1121 Scientists find "alternative" targets for the treatment of leukemia [IGF2GP3]
Researchers from the University of California, USA, published a new research advance in the international academic journal JCI, they performed gene expression analysis of a B-cell acute lymphoblastic leukemia commonly found that a RNA-binding protein called IGF2BP3 was expressed very abundantly in patients, and proved that this protein plays a very important driving role in the occurrence of this type of leukemia.
IGF2BP3 is normally expressed in fetal tissues and is completely turned off in adults. This protein is an RNA-binding protein that binds to mRNA and regulates gene expression after transcription, and there is currently less research on RNA-binding proteins regulating gene activity than other proteins that regulate gene activity.
DMDRMR is a long-chain non-coding RNA regulated by m6A, which can be used as a stable target gene and tumor-promoting synergistic molecule for the m6A reading protein IGF2BP3, not only that, but also provides a theoretical basis for new policies and new targets for the clinical diagnosis and treatment of renal transparent cells.
Both DNA methylation modifications and long noncoding RNAs can be involved in the regulation of multiple biological processes of tumors. The former is an important regulatory method of epigenetics, which can accurately regulate gene expression; the latter can also regulate gene expression at multiple levels.
It is reported that at present, dna methylation abnormal regulation coding gene profile has been extensively studied, and it has been confirmed that it drives the occurrence and development of tumors. However, the expression profiles of lncRNAs regulated by ABNORMAL DNA methylation and their tumor-driving functions need to be further studied.